仑伐替尼单药治疗美国不可切除肝细胞癌患者的真实世界疗效。
Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA.
机构信息
Division of Digestive & Liver Disease, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Department of Health Economics, RTI Health Solutions, Research Triangle Park, NC 27709, USA.
出版信息
Future Oncol. 2021 Jul;17(21):2759-2768. doi: 10.2217/fon-2021-0242. Epub 2021 Apr 9.
This study evaluated the effectiveness of lenvatinib monotherapy for first-line treatment of unresectable hepatocellular carcinoma (uHCC) in a real-world setting. This retrospective cohort study included patients who initiated lenvatinib monotherapy as first-line treatment for uHCC (n = 233). Clinical outcomes included provider-reported best response, progression-free survival (PFS) and overall survival (OS). PFS and OS were estimated using Kaplan-Meier methods. Most patients (67.8%) were male. A total of 44.6% had Child-Pugh A and 39.1% had Child-Pugh B. Dose reductions were reported in 9%. Median PFS and OS were not reached. At 6 and 12 months, landmark PFS were 85.1 and 64.9%, respectively; landmark OS were 91.8 and 72.6%, respectively. These results affirm the clinical effectiveness of first-line lenvatinib monotherapy in uHCC.
本研究评估了仑伐替尼单药治疗不可切除肝细胞癌（uHCC）一线治疗的有效性。这是一项回顾性队列研究，共纳入了 233 例接受仑伐替尼单药一线治疗 uHCC 的患者。临床结局包括提供者报告的最佳反应、无进展生存期（PFS）和总生存期（OS）。采用 Kaplan-Meier 方法估计 PFS 和 OS。大多数患者（67.8%）为男性。共有 44.6%的患者 Child-Pugh A，39.1%的患者 Child-Pugh B。有 9%的患者报告了剂量减少。中位 PFS 和 OS 均未达到。6 个月和 12 个月时的 landmark PFS 分别为 85.1%和 64.9%，landmark OS 分别为 91.8%和 72.6%。这些结果证实了仑伐替尼单药一线治疗 uHCC 的临床疗效。
Zotero 插件